Makana Therapeutics Logo
ABOUT US
Founded in 2009, Makana Therapeutics is focused on developing pigs with reduced xenoantigen expression, making human transplantation of cells, tissues and organs from these animals possible. Makana’s focus on simplified genetics, optimized pig cloning techniques and careful patient selection (including a proprietary crossmatch assay) is expected to streamline product development and result in safer, more efficacious products.
Mark Platt, President & CEO of Makana Therapeutics, discusses the promise of xenotransplantation.